| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/05/2013 | US20130231313 Substituted phenylacetate and phenylpropane amides and use thereof |
| 09/05/2013 | US20130231312 Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers |
| 09/05/2013 | US20130231311 Novel formulations for treatment of migraine |
| 09/05/2013 | US20130231308 Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome |
| 09/05/2013 | US20130231307 Novel antiviral acyclic nucleoside phosphonates |
| 09/05/2013 | US20130231301 Combination of checkpoint kinase i inhibitors and wee i kinase inhibitors |
| 09/05/2013 | US20130231300 Purified Crocetin Compound And Method For Treating, Inhibiting, And/Or Prophylaxis of Cancer, Such As Pancreatic Cancer |
| 09/05/2013 | US20130231296 New drug combinations for the treatment of malaria |
| 09/05/2013 | US20130231292 Synergistic anti-proliferation activity of TAS-108 with mTOR inhibitors against cancer cells |
| 09/05/2013 | US20130231286 Use of Prolactin Receptor Antagonist and Chemotherapeutic Drug for Treating Ovarian Cancer |
| 09/05/2013 | US20130231282 Methods for administering hypoglycemic agents |
| 09/05/2013 | US20130231277 Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders |
| 09/05/2013 | US20130231275 Aminiothiazoles and their uses |
| 09/05/2013 | US20130230606 Methods and compositions for regulating biofilm development |
| 09/05/2013 | US20130230600 Therapeutic agent |
| 09/05/2013 | US20130230587 Sustained release compositions |
| 09/05/2013 | US20130230547 Methods and compositions for prostate cancer immunotherapy |
| 09/05/2013 | US20130230542 ROS-Activated Compounds as Selective Anti-Cancer Therapeutics |
| 09/05/2013 | US20130230541 Anti-igf antibodies |
| 09/05/2013 | US20130230530 Human antibodies that bind cd22 and uses thereof |
| 09/05/2013 | US20130230527 Emp2 antibodies and their therapeutic uses |
| 09/05/2013 | US20130230522 Complement Pathway Inhibitors Binding To C5 and C5A Without Preventing The Formation of C5B |
| 09/05/2013 | US20130230520 Pharmaceutical composition for treating bone diseases which comprises protein comprising frizzled1, frizzled2 or frizzled7 extracellular cysteine-rich domain |
| 09/05/2013 | US20130230514 Compositions of pd-1 antagonists and methods of use |
| 09/05/2013 | US20130230512 Inhibitors of the atb(0,+) transporter and uses thereof |
| 09/05/2013 | US20130230510 Method of inhibition of leukemic stem cells |
| 09/05/2013 | US20130230506 Methods for increasing intracellular activity of hsp70 |
| 09/05/2013 | US20130230499 Cellular blood markers for early diagnosis of als and for als progression |
| 09/05/2013 | US20130230498 Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities |
| 09/05/2013 | US20130230494 Cellular Preparations For Wound Management |
| 09/05/2013 | US20130230489 Paediatric Compositions For Treating Multiple Sclerosis |
| 09/05/2013 | US20130230485 Methods for Treating Patients Undergoing Multi-Cycle Chemotherapy |
| 09/05/2013 | US20130230458 Cell Permeable Inhibitors of Anaphase Promoting Complex |
| 09/05/2013 | US20130230453 Diagnosis and treatment of brain tumors |
| 09/04/2013 | EP2633868A1 Combination of alpha 7 nicotinic agonists and antipsychotics |
| 09/04/2013 | EP2632490A2 Novel egfr-binding molecules and immunoconjugates thereof |
| 09/04/2013 | EP2632489A2 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy |
| 09/04/2013 | EP2632459A2 Method of treating neuroendocrine tumors |
| 09/04/2013 | EP2632268A2 Novel compounds that are erk inhibitors |
| 09/04/2013 | CN103282050A Antitumor combinations containing antibodies recognizing specifically CD38 and bortezomib |
| 09/04/2013 | CN103282037A Combination therapy with an antitumor alkaloid |
| 09/04/2013 | CN103275159A Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 09/04/2013 | CN103272236A Beta-adrenergic receptor retarder and vitamins B-containing pharmaceutical composition and applications thereof |
| 09/04/2013 | CN103272235A Pharmaceutical composition for preventing or treating cold injury and thrombus |
| 09/04/2013 | CN103272234A Pharmaceutical compositions |
| 09/04/2013 | CN101926998B Expression of embryo type globin induced by adrenoreceptor agonist and application thereof |
| 09/04/2013 | CN101797386B Novel nerve protective agent |
| 09/04/2013 | CN101631477B Liquid nutritional food and method of producing the same |
| 09/04/2013 | CN101269214B EG-VEGF nucleotide and using method |
| 09/03/2013 | US8524871 Modified gherlin peptides |
| 09/03/2013 | US8524711 Amino-derivatives as novel inhibitors of histone deacetylase |
| 09/03/2013 | US8524701 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 09/03/2013 | US8524665 Use of secretin in treatments of disorders associated with the amygdala |
| 09/03/2013 | US8524660 Polyalkylene polymer compounds and uses thereof |
| 09/03/2013 | US8524279 Atomizing nozzles include a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas; spray drying at a commercial plant scale. |
| 09/03/2013 | US8524266 Polymers of fluorinated monomers and hydrocarbon monomers |
| 09/03/2013 | CA2729854C Combination of a parp inhibitor and an akt kinase activating compound |
| 09/03/2013 | CA2707691C Sphingomyelin containing preparation |
| 09/03/2013 | CA2526541C Novel biomaterial drug delivery and surface modification compositions |
| 09/03/2013 | CA2489308C Use of taurine for the treatment of alopecia |
| 09/03/2013 | CA2421865C Olfactory and pheromones g-protein coupled receptors |
| 08/29/2013 | WO2013126799A1 Compositions and methods for ocular delivery of a therapeutic agent |
| 08/29/2013 | WO2013126776A1 Nanostructures for treating cancers and other conditions |
| 08/29/2013 | WO2013126636A1 Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy |
| 08/29/2013 | WO2013124860A1 Potent revital formulation |
| 08/29/2013 | WO2013124286A1 Novel neurokinin 1 receptor antagonist compounds |
| 08/29/2013 | US20130225688 Compositions and methods for the treatment of somatosensory disorders |
| 08/29/2013 | US20130225682 Use of Medium Chain Triglycerides for the Treatment and Prevention of Alzheimer's Disease and Other Diseases Resulting from Reduced Neuronal Metabolism II |
| 08/29/2013 | US20130225674 Use of dibenzofuranone derivatives to inhibit kinases |
| 08/29/2013 | US20130225655 Combinations of TGFBeta and COX-2 Inhibitors and Methods for Their Therapeutic Application |
| 08/29/2013 | US20130225646 Substituted n-phenethyltriazoloneacetamides and use thereof |
| 08/29/2013 | US20130225643 Endogeneous repair factor production accelerators |
| 08/29/2013 | US20130225634 Anti-cancer compounds |
| 08/29/2013 | US20130225628 Carboxamide bioisosteres of opiates |
| 08/29/2013 | US20130225626 Sublingual films |
| 08/29/2013 | US20130225620 Serine/threonine kinase inhibitors |
| 08/29/2013 | US20130225616 Crystalline form of pyrimidio[6,1-a] isoquinolin-4-one compound |
| 08/29/2013 | US20130225614 4-azolylaminoquinazoline derivatives and methods of use thereof |
| 08/29/2013 | US20130225603 Mdm2 inhibitors for treatment of ocular conditions |
| 08/29/2013 | US20130225595 Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis |
| 08/29/2013 | US20130225580 Aza-aryl 1h-pyrazol-1-yl benzene sulfonamides |
| 08/29/2013 | US20130225578 7-cyclylquinazoline derivatives and methods of use thereof |
| 08/29/2013 | US20130225575 Methods for treating neurological conditions |
| 08/29/2013 | US20130225574 Oxazolidin-2-one compounds and uses thereof |
| 08/29/2013 | US20130225569 Furopyridine derivatives |
| 08/29/2013 | US20130225566 Pharmaceutical combinations for the treatment of metabolic disorders |
| 08/29/2013 | US20130225562 Pyridyltriazoles |
| 08/29/2013 | US20130225554 New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
| 08/29/2013 | US20130225551 Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer |
| 08/29/2013 | US20130225543 Specific regulation of cytokine levels by hdac6 inhibitors |
| 08/29/2013 | US20130225531 Method and composition for treating alzheimer's disease and dementias of vascular origin |
| 08/29/2013 | US20130225530 Wogonin for the prevention and therapy of cardiac hypertrophy |
| 08/29/2013 | US20130225529 Phospho-ester derivatives and uses thereof |
| 08/29/2013 | US20130225524 Chemical Compounds |
| 08/29/2013 | US20130225517 Therapeutic Compounds |
| 08/29/2013 | US20130225516 Topical compositions comprising fipronil and permethrin and methods of use |
| 08/29/2013 | US20130225510 Methods for the use of branched chain amino acids |
| 08/29/2013 | US20130225503 Tex14 peptides as novel antitumor agents |
| 08/29/2013 | US20130225499 Method for administering omega-conopeptide |
| 08/29/2013 | US20130225495 Formulations having an antagonist of alpha 5 beta 1 for anti-angiogenesis and cancer treatment |